Chapter 123 Imitation
Based on the requirements of the headquarters, Tian Hemeng proposed a 1 billion procurement plan.
Among them, the quota for imported drugs is 500 million yuan, and the quota for production line purchases is 500 million yuan. It is also promised that when purchasing drugs from outside in the future, priority will be given to purchasing from Zhengda Company.
Xie Bin's eyes almost lit up as he looked at the list of imported drugs in his hand.
The above lists [Entecavir Dispersible Tablets], [Magnesium Isoglycyrrhizinate Injection], [Diamonium Glycyrrhizinate Enteric-coated Capsules], [Entecavir Maleate Tablets], [Irbesartan Hydrochlorothiazide Tablets], [Survastatin Calcium Tablets ], [Alprostadil Injection], etc., a total of 44 kinds of drugs have been imported.
Some of these medicines are needed by Qingye Pharmacy, and some are needed by Qingye Hospital.
However, Xie Bin does not have the authority to decide on the introduction of production lines, but he estimates that the headquarters will not refuse. After all, if Zhengda Company does not sell it, other companies will.
Qingye Medical requires many production lines, mainly concentrated in three areas: cardiovascular and cerebrovascular, anti-tumor, orthopedics, analgesia, and supplements.
As for drugs for liver diseases, respiratory system, and digestive system, they are not on the list. Mainly these drugs, Qingye Medical will develop them on its own in the future and will not need Zhengda’s production line.
A total of 13 drug production lines were selected.
After communication between Xie Bin and the headquarters, the two sides quickly reached an agreement that Zhengda Pharmaceutical would package and sell a batch of drug production lines that were about to be eliminated or had already been eliminated to Qingye Medical.
After signing the contract, CP Group's reserves in Aoba Bank increased to more than 500 million.
However, Charoen Pokphand Company has no intention of taking the money. After all, the money must be spent. As the effect of AIDS-free spreads outward, and many regions have not approved the sale of AIDS-free, this means that for a period of time, Hongsavady, Siam, and Luzon will become the main channels for AIDS patients around the world to obtain drugs.
…
If we talk about the specific drug for AIDS - AIDS Zero, it has only aroused some interest in various parts of the world.
Then rabies killer becomes a necessity in many underdeveloped areas.
After all, these underdeveloped areas do not have the conditions to popularize rabies vaccines, whether it is for humans or pets, the coverage rate is not high enough.
For example, in Siam, there was a large-scale rabies outbreak in 2018.
Many people who have been scratched and bitten by cats and dogs generally do not have enough awareness of prevention, or think that the price of rabies vaccine is too high, so they do not get the rabies vaccine in time. Then when the disease occurs, it is basically incurable.
Although rabies killer is very expensive, its importance increases sharply due to its effectiveness during the disease period.
Of course, Tian Hemeng knew that at the current price, only a few companies would be willing to purchase Rabies Killer.
Therefore, the production capacity of the Rabies Killer production line is very low. Even if the production line is fully operational, it can only produce 20,000 boxes per month. Moreover, it is currently only operated for an average of 3 hours a day, so the monthly production capacity is only 2,000 boxes.
The production volume is low and the demand is not high, so the sales price is naturally high.
For this kind of niche drugs, Qingye Medical concentrates them in a small town near Taunggyi and conducts joint production.
Usually one drug is produced normally for one week, and then the employees are transferred to the next production workshop to produce another drug, and the cycle repeats itself.
Using this production plan is also a last resort.
After all, this is the fate of niche drugs. The market is so small, and it is too difficult to maintain a production line at full capacity.
Otherwise, Qingye Medical would not have limited the sales of Ai Qingling because it was worried that the market would be saturated all of a sudden and the production line would be scrapped.
This is also the reason why many large pharmaceutical companies do not like to develop radical cure drugs.
It's all about profit.
…
Also for profit.
Hundreds of generic drug companies in Tianzhu have also recently taken action in response to the news.
A large generic drug company based in Mumbai has already procured some Aiqingling through the Indians in Yangon.
In the laboratory, the boss Ali asked eagerly, "Dr. Kesha, how is the research going?"
Dr. Kesha, who was wearing a white coat, shook his head and said, "Mr. Chairman, I'm very sorry, but I'm afraid we can't make a copy of this drug."
"Why?" Ali asked unwillingly, "Is it because our equipment is not good enough?"
"Mr. Chairman, this is not a problem with the equipment, but we don't have the raw materials." Dr. Kesha spread his hands.
Ali frowned: "Raw materials?"
"Yes, it's the raw material. This new drug requires special bacteria, similar to penicillin and streptomycin."
"Then let's go buy some fungus!"
Dr. Kesha's mouth twitched slightly: "Haha, the key is that Qingye Medical did not announce what kind of bacteria it used as raw materials. Based on my experience, it is definitely not a common medicinal bacteria."
"Damn it! These greedy vampires actually concealed such crucial information."
Haha, Dr. Kesha complained secretly, you want to imitate other people's new drugs, but you blame others for not disclosing the technical details. Can you please not be so shameless?
Ali suddenly had an idea: "I heard that antibiotics can be synthesized artificially now. Can we try to produce them using this method?"
"Uh... Mr. Chairman, the active ingredients of the other party's new drugs are all large molecular organic substances. To synthesize them artificially, we must first figure out which part of the structure of this large molecule is working. Moreover, this kind of research requires a lot of funds and a long time..." Dr. Kesha explained helplessly.
When Ali heard that it would require a large amount of money and a long time, he immediately showed a disappointed expression.
Generic drug companies like his rely on imitating new drugs developed by others. It is basically impossible to expect them to invest huge amounts of money to develop a drug with an uncertain future.
In fact, it is not just the Indian generic drug companies that are secretly researching imitations.
Even major pharmaceutical companies in Europe and the United States are secretly studying how to imitate it.
But they all encountered the same problem.
That is, what kind of bacteria did Qingye Medical use to isolate these three new antibiotics. Now European and American pharmaceutical companies have not found similar macromolecules, so they can only study the structure of these macromolecules, hoping to find some effective antiviral structures from them, and then learn from and improve them.
So what kind of bacteria does Qingye Medical use?
The answer is genetically recombinant bacteriophages. These phages have been transformed beyond recognition by Li Qingye, and then these phages are used to fight against HIV, and then those phages that can resist and kill HIV are selected.
In other words, the bacteria that produce the new antibiotics are not naturally occurring bacteria. Other laboratories have no way of obtaining this genetically modified bacteria, and they cannot imitate it in a short period of time.
This is just like when penicillin first came out, those high-yield bacterial strains were the core secrets of every pharmaceutical company and even every country.
Without high-yield strains, the production cost of ordinary penicillin is comparable to gold.
The strains of bacteria used by Qingye Medical do not even exist in nature, and other laboratories cannot even extract small amounts. Faced with this situation, how can they be imitated?
You should know that this is not an ordinary inorganic chemical drug, but an organic macromolecule, which is extremely difficult to synthesize artificially.
This is also one of the advantages of targeted antibiotics. Without sufficiently powerful genetic technology, there is no way to imitate targeted antibiotics in a short period of time.
